MedTrace Logo

Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML

NCT05463640 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-07-19

No results posted yet for this study

Summary

This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia

Conditions

Interventions

BIOLOGICAL

ADGRE2 CAR-T

ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • He Huang, MD · The first hospital affiliated Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2024-08-02
Completion
2025-08-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05463640 on ClinicalTrials.gov